Triastek Unveils 2.0 Open Strategy to Accelerate Global Commercialization of 3D-Printed Pharmaceuticals
On October 27, TRIASTEK (Nanjing) Pharmaceutical Technology Co., Ltd. (“TRIASTEK”), a global leader in the field of 3D-printed pharmaceuticals, disclosed its corporate development roadmap and open strategy for the 2.0 era:By leveraging open technical resources and establishing extensive collaborations with global pharmaceutical companies, commercialize 3D-printed drug technology.
TRIASTEK was founded in July 2015 by Dr. Senping Cheng, an entrepreneur with startup experience in both China and the United States, and Dr. Xiaoling Li, a renowned international pharmaceutical scientist and educator.TRIASTEK is an international pharmaceutical company driven by the dual cores of 3D-printed drug R&D and equipment development, dedicated to building a novel 3D-printed drug technology platform and establishing proprietary technologies covering the entire chain from drug dosage form design and digital development to intelligent manufacturing.
Dr. Senping Cheng, Founder and CEO of TRIASTEK, stated, “After six years of innovation and entrepreneurship, TRIASTEK is poised for significant growth. While continuing to drive technological innovation, TRIASTEK will leverage its platform technology to serve global pharmaceutical companies and promote the digitalization and intelligent transformation of the formulation industry.”
Dr. Senping Cheng, Founder and CEO of TRIASTEK
The birth of TRIASTEK stemmed from “a scientific hypothesis, a dream to change the world.” In July 2015, TRIASTEK was established in Nanjing. From its inception, the company set forth its vision to “become a globally influential intelligent pharmaceutical enterprise” and outlined a three-stage development roadmap.
TRIASTEK 2.0 Era Open Strategy
From 2015 to 2019, during the TRIASTEK 1.0 era, the company adopted an intellectual property-driven strategy and completed the development of its 3D-printed drug platform technology.
From 2020 to around 2025, during the TRIASTEK 2.0 era, the company established extensive commercial collaborations with global pharmaceutical enterprises to fully leverage the value of emerging technologies.
Starting in 2026, TRIASTEK will enter the 3.0 era, becoming a key global provider of intelligent pharmaceutical technologies.
As the first and currently only company in China specializing in 3D-printed pharmaceuticals, TRIASTEK’s inaugural 3D-printed drug product, T19, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)., and submitted to the China National Medical Products Administration (NMPA) as a Class 2.2 improved new drug, with an NDA submission to the FDA expected in 2023.
Currently, TRIASTEK has filed 127 patent applications worldwide, accounting for more than 20% of the global total in the field of 3D-printed pharmaceuticals. It is the company with the most comprehensive patent portfolio and the highest number of patent applications in this sector. Among the four 3D-printed drug products that have entered or completed regulatory registration globally, three were developed by TRIASTEK.
In July 2020, the United States Pharmacopeia (USP) formally invited TRIASTEK to participate in the development of industry standards for 3D-printed pharmaceuticals.
Technological innovation has always been the engine driving sustained growth in the pharmaceutical industry.
TRIASTEK's MED®(Melt Extrusion Deposition) 3D printing drug production technology is a new technique widely applicable to solid dosage forms.
TRIASTEK MED 3D-Printed Drug Production Line V2.5 (Prototype Production Line)
This 3D printing technology, tailored for drug manufacturing, boasts strong universality and has completely revolutionized traditional drug product development and pharmaceutical production methods., revolutionizing traditional pharmaceutical manufacturing processes, redefining the underlying logic, process workflows, and production models of formulation technology based on Industry 4.0, and achieving continuous, intelligent drug production with real-time quality control.
TRIASTEK's 3DFbD®Product development approach: upgrading from “traditional trial-and-error formulation development” to a digital formulation development paradigm of “formulation by design,” significantly reducing development time and costs.
By designing dosage forms with internal three-dimensional structures, precise control over the timing, location, and rate of drug release can be achieved. This approach allows for flexible combinations of drug release mechanisms, addressing challenging dosage form designs and release profiles. Consequently, it enhances the efficacy of pharmaceutical products, reduces side effects, improves patient friendliness, and provides a rich array of product design strategies to meet diverse clinical needs.
Dr. Cheng Senping stated, “Currently, TRIASTEK’s 3D-printed drug manufacturing equipment has undergone more than ten iterations, with ten product pipelines in development. By the end of this year, TRIASTEK will establish a continuous 3D-printed drug production line with an annual capacity of 50 million tablets.”
Established six years ago, TRIASTEK has completed five rounds of financing to date, with investors including Tasly Group, Morningside Venture Capital, Volcanic Stone Investment, Daotong Investment, Yunqi Partners, Matrix Partners China, CPE Yuanfeng, Shanghai Science and Technology Innovation Fund, and Qinzhi Capital, among other renowned institutions.